Navigation Links
Lloyd Wright's Alternative Medicine Has One of its Hepatitis C Viral Inhibitors Given Boost as Scripps Study Peptides Effectiveness

In a ground breaking study, Scripps Research has proved that peptides are extremely effective in slowing down and actually fighting the Hepatitis C virus. Lloyd Wright, author of Hepatitis C Free, has a number of Natcell products that contain peptides. "We went for the simplest solution, taking a peptide from core to see if we could block the interaction, and it did,” said Professor Strosberg.

(PRWEB) November 18, 2009 -- Lloyd Wright, author of Triumph Over Hepatitis C and President of Alternative Medicine, Inc., was recently proven correct regarding the effectiveness of one his Hepaptitis C viral inhibitors. Peptides, which are part of Alternative Medicine’s complete line of Natcell product line, have been found in a study conducted the Scripps Research Institute to inhibit “the joining of core proteins and the production of the actual virus itself.” Professor Donny Strosberg, who led this study for Scripps Florida, related how researches described “peptides, molecules of two or more amino acids, derived from the core protein of hepatitis C. We went for the simplest solution, taking a peptide from core to see if we could block the interaction, and it did.”

This study reaffirms what Lloyd Wright already knew from his own battle with Hepatitis C, which is chronicled in his fascinating book Triumph Over Hepatitis C. His battle, which involved a variety of natural therapies, led him to pioneer a number of products that are sold around the world and helping scores of people afflicted with this debilitating virus. For example, “Lloyd’s TLM Econo product package, which is shipped frozen, contains “a winning combination of Natcell Thymus, Natcell Liver and Natcell Mesenchyme specially designed to fight Hep C and heal the liver.” This is only one in an extensive Natcell product line, all of which contain Peptides. For more info call 877-676-1615 or go to

Below are detailed conclusions from the Scripps Research Institute led by Professor Strosberg on Peptides:

The Problem with Hepatitis C
With over 170 million people infected worldwide by HCV, new therapeutic strategies for HVC—a blood-borne disease that affects the liver—are urgently needed.

But one of the critical problems in developing drugs for HCV is that it mutates at such prodigious rates. An RNA virus like hepatitis C can mutate at a rate estimated as high as one million times that of DNA viruses; in contrast, DNA viruses contain an enzyme (polymerase) that acts as something of a proof reader to ensure that newly transcribed DNA strands are the same as the original, helping to reduce mutations.

"In one sense, the ongoing issue with hepatitis C is that there are still so very few drugs to treat the virus and very few tools to study it," Strosberg said. "We set out to develop new tools and to identify a new target – core, the capsid protein. By targeting the interactions of core with itself or other proteins, we could reduce the problem of rapid mutation not only because the core protein mutates significantly less, but also because mutations that would affect the interface between core and itself or other proteins would often be more likely to deactivate the virus, in contrast to mutations in viral enzymes which often lead to increased resistance to drugs."

Recent efforts to develop therapeutic strategies against HCV have concentrated on designing inhibitors that target several of the 10 HCV proteins that comprise the virus, including mostly the non-structural proteins. However, as the study points out, the one HCV structural protein that has not been targeted yet is the core protein, the one responsible for assembly and packaging of the HCV RNA genome.

The Core of the Matter
Core, the most conserved protein among all HCV genotypes, plays several essential roles in the viral cycle in the host cell; studies have suggested that these core-core or core-other protein interactions can modulate various functions including signaling, apoptosis or programmed cell death, lipid metabolism, and gene transcription.

The core protein is particularly important in the assembly of the hepatitis C nucleocapsid, an essential step in the formation of infectious viral particles; the nucleocapsid is the viral genome protected by a protein coat – the capsid. This core protein plays an essential role in the HCV cycle during assembly and release of the infectious virus, as well as disassembly of viral particles upon entering host cells.

Looking closely at the core interaction with itself, Strosberg developed several novel quantitative assays or tests for monitoring these protein-protein interactions with the specific goal of identifying inhibitors of the core dimerization, which would block virus production.

"People have been dreaming about inhibiting protein-protein interactions, as a new El Dorado for finding novel drug targets," says Strosberg, "but few conclusive studies have emerged, except in the virus-host area."

Inhibition of HCV Production
The new research, however, led to the discovery of two peptides that inhibited HCV production by 68 percent and 63 percent, respectively; a third related peptide showed 50 percent inhibition. When added to HCV-infected cells, each of the three peptides blocked release but not replication of infectious virus; viral RNA levels were reduced by seven fold. Strosberg notes that the efficacy of small molecules like these can often be improved over initial levels.

"After we'd finished our work, we learned that Frank Chisari – one of the leading experts on HCV who works at Scripps Research in La Jolla – had been looking at similar peptides using a very different approach," said Strosberg. "One of his peptides was the same as ours – it also inhibited virus production. It's an incredible coincidence and a confirmation of our study."

Journal reference:
1.   Smitha Kota et al. Peptide Inhibitors of Hepatitis C Core Oligomerization and Virus Production. Journal of General Virology, Online March 4, 2009 DOI: 10.1099/vir.0.008565-0
Adapted from materials provided by Scripps Research Institute.

About Lloyd Wright:
A series of medical problems began for Lloyd Wright in 1979 when, following a bad tractor accident, he was given a blood transfusion tainted with Hepatitis C. Thus began a decade long struggle with unexplained health problems, many involving excruciating pain and befuddled doctors. Then in 1993, through a quirk of fate, his blood was tested and it was revealed that Wright had Hepatitis C, which actually explained the chronic problems which plagued his every day life.

He was told to get his affairs in order, but Lloyd Wright was made of sterner stuff than to just roll over and die. He found a natural cure and, despite the derision of mainstream media, remains free of Hepatitis C while he helps scores of suffering people with his natural cures. He proved all the skeptics wrong and continues to live a healthy life, while also bringing a message of hope to people all over the world. For more information about his innovative cures for Hepatitis C and his Blueberry Extract go to

Lloyd Wright’s Natcell is comprised of Peptides. Please contact 877-676-1615 or go to for more information.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin
2. Lloydspharmacy Reveals Hayfever Misery to Hit One in Two People by 2060
3. Darwins Kim Lloyd to Speak on Panel at American Hospital Association Solutions Roundtable, June 3, 2009
4. Lloyd I. Miller III Announces Voting Intentions for United American Healthcares Annual Meeting
5. Ricky Tomlinson Joins Lloydspharmacy Against Coronary Heart Disease
6. InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group
7. Delaware Hospice Honors President and CEO Susan D. Lloyd, MSN, RN
8. When East meets West: Why consumers turn to alternative medicine
9. Alternative to Warfarin May Cut Risk of Bleeding
10. Stem Cells May Offer Alternative to Lung Transplants
11. Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations
Post Your Comments:
Related Image:
Lloyd Wright's Alternative Medicine Has One of its Hepatitis C Viral Inhibitors Given Boost as Scripps Study Peptides Effectiveness
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also known ... people who find their cholesterol levels and weight are creeping up are more likely ... don’t have any of the other symptoms. , Thyroid hormone plays a major role ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis ... Care Plan software creates an agreement between the practice owner and the patient ... scheduling, monitoring, notification, and projections. Click here to learn more. ...
(Date:11/24/2015)... ... , ... Charitable giving is at its peak during the holidays. In ... of the year totalling over $358 billion in 2014. With more than 1.5 ... those individuals who want to “give back” during the holidays. , “With so many ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... national leaders when it comes to several aspects of orthopedic care. They have ... replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review selected ...
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  In the ... projects in an effort to quickly uncover new insights, ... --> --> However, ... a market research project and ensure that all rules ... and industry standards. Another major barrier to efficiently launching ...
(Date:11/24/2015)... Va. , Nov. 24, 2015  DILON Diagnostics ... have signed an agreement for DILON to distribute GE,s ... across the globe. The signing of this distribution agreement will ... NM750b Molecular Breast Imaging system and is considered an ... provide better healthcare solutions for clinicians and their patients. ...
Breaking Medicine Technology: